ALK and non-small cell lung carcinoma: In NSCLC patients, anaplastic lymphoma kinase (ALK) gene or ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) rearrangement accounts for 5 and 1%, respectively [85].